(Q36960497)

17 August 2017

1 reference

title

Tuberculosis subunit vaccines: from basic science to clinical testing (English)

1 reference

17 August 2017

1 reference

T Mark Doherty

1

1 reference

17 August 2017

Jes Dietrich

series ordinal

2

1 reference

17 August 2017

Rolf Billeskov

series ordinal

3

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 October 2007

1 reference

Expert Opinion on Biological Therapy

17 August 2017

published in

1 reference

17 August 2017

volume

7

1 reference

17 August 2017

issue

10

1 reference

17 August 2017

page(s)

1539-1549

1 reference

Does the protective effect of neonatal BCG correlate with vaccine-induced tuberculin reaction?

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Efficacy of BCG vaccination of the newborn: evaluation by a follow-up study of contacts in Bangui

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Decreased survival of guinea pigs infected with Mycobacterium tuberculosis after multiple BCG vaccinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Tuberculosis vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Bacillus Calmette-Guérin vaccination and infant mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Beyond BCG: the potential for a more effective TB vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Ethical issues in tuberculosis vaccine trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Cell-mediated immunity induced by recombinant Mycobacterium bovis Bacille Calmette-Guérin strains against an intracellular bacterial pathogen: importance of antigen secretion or membrane-targeted antigen display as lipoprotein for vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

The T cell response to secreted antigens of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Prospects for a novel vaccine against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Translational mini-review series on vaccines: Development and evaluation of improved vaccines against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Evaluation of adjuvants for protein vaccines against tuberculosis in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Evaluation of vaccines to prevent childhood pneumonia: lessons relevant to planning tuberculosis vaccine trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Association of tuberculin-boosted antibody responses with pathology and cell-mediated immunity in cattle vaccinated with Mycobacterium bovis BCG and infected with M. bovis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Correlation of ESAT-6-specific gamma interferon production with pathology in cattle following Mycobacterium bovis BCG vaccination against experimental bovine tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

The prognosis of latent tuberculosis: can disease be predicted?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Lack of protection in mice and necrotizing bronchointerstitial pneumonia with bronchiolitis in guinea pigs immunized with vaccines directed against the hsp60 molecule of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Potential public health impact of new tuberculosis vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Vaccine strategies against latent tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

DNA immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Pulmonary necrosis resulting from DNA vaccination against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Therapy of tuberculosis in mice by DNA vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Comparative Analysis of Different Vaccine Constructs Expressing Defined Antigens fromMycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Cytolytic T-cell responses to human dendritic cells and macrophages infected with Mycobacterium bovis BCG and recombinant BCG secreting listeriolysin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Synergistic Effect of Bacillus Calmette Guerin and a Tuberculosis Subunit Vaccine in Cationic Liposomes: Increased Immunogenicity and Protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.10.1539

10.1517/14712598.7.10.1539

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference